Previous editions of BioBucks

Biogen shops immunology, Kardigan banks $400M, and biotech tapes over a weak broader close.

Moderna faces the FDA panel, Lilly grabs more pain, and Merck writes another AI check.

Intellia rewrites HAE, Spyre stokes TL1A takeout math, and Neumora cuts a third of staff.

J&J leads on Phase 3 myeloma, Sanofi expands Tzield, and Lilly adds a CLL win as biotech stays bid.

Takeda bodies Sotyktu in a head-to-head, Penumbra gets its stroke green light, and Stockholm keeps the EHA data spigot open.

Hot CPI and an oil-fueled risk-off dragged biotech down with the tape — even a record IPO and a Phase 3 win couldn't keep the screen green.

GSK reaches for the checkbook, Parabilis breaks the IPO record, and AstraZeneca gatecrashes the GLP-1 party.

Incyte spends $2B dodging its own patent cliff, J&J buys into degraders sight-unseen, AZ's diet pill stays in the race — and biotech somehow still closes red.

Roche hands Nurix $700M for a BTK degrader, ADA can't stop shipping obesity data, and a chip rout drags the tape to its worst day since October.

First CLDN18.2 ADC into a regulatory queue, Otsuka fights for its Voyxact read, and a new bill takes aim at the China licensing trade.

Biotech outpaced a softer tape as Alnylam struck a $2B AI pact, Lilly licensed Ascidian's RNA editing, and Iovance added Australia.

J&J's nipocalimab delivers in SLE, Travere strikes a $1B kidney licensing deal, and Novo exports oral Wegovy.

Roche lands Priority Review, Abivax’s UC readout gets a safety asterisk, and biotech lags a still-risk-on tape.

Ivonescimab flexes on OS, daraxonrasib doubles survival in pancreatic cancer, and Lilly licenses a gut hormone before lunch.

Pfizer inks a 12-asset oncology pact, SHINE wins Europe for Ilumira, and healthcare finally leads the tape.

$1.3B for Apogee with zero dilution, a hepatitis B functional cure from GSK, and a faster FDA clock for Sanofi.

Lilly buys three vaccine makers for up to $3.8B, EMA's CHMP greenlights four, and Kardigan tests the IPO window.

Lilly posts early Verve data, ASCO names to watch sharpen, and neuromuscular FDA clocks speed up.

Lilly's triple agonist hits Phase 3 in obesity, Biogen and Denali scrap BIIB122, and Retro lands at a $1.8B valuation.

BioMarin lands Phase 3 data, Lilly adds delivery tech, and cAMPfield puts up a $180M Series A.

Paragon's Mentari hits Nasdaq via reverse merger with $290M PIPE, Relay scores in vascular anomalies and tags a $175M raise, and Regeneron seeds a $2.3B Helicon bet at Parabilis.

Hansa’s licensing win, private cash, and a softer biotech tape set the tone.

Candel adds follow-up ahead of filing, Aardvark hits a hold, and FDA leadership churn clouds the setup.

Track 2026 biotech/biopharma licensing + partnering deals — upfronts, milestones, royalties, rights/territory, and a one-line “why it matters.”

Diranersen lives, RGX-202 hits with a safety asterisk, and Alumis tees up a strategic review.